Evotec Announces CFO Transition: Paul Hitchin Steps Down, Claire Hinshelwood Appointed
EVO sits 33% above its 52-week low of $2.308 on elevated volume (4.9× avg).
Summary
Evotec SE announced a change in its Chief Financial Officer role, with Paul Hitchin stepping down for personal reasons and Claire Hinshelwood, an experienced financial leader, appointed as his successor.
Key Events · Executive and Board Changes · EVO
-
Chief Financial Officer Departure
Paul Hitchin will step down as Chief Financial Officer of Evotec SE on April 30, 2026, for personal reasons unrelated to the company.
-
New CFO Appointment
Claire Hinshelwood has been appointed as the new Chief Financial Officer, effective May 1, 2026. She brings over 30 years of financial leadership experience, including roles at BMI Group, Novartis, and Syngenta.
-
Strategic Focus
The company expects the new CFO's expertise to advance its progress toward increased profitability and sustainable growth during its ongoing business transformation.
Analysis · EVO · Life Sciences
The transition in Evotec's Chief Financial Officer role is a significant leadership change. While Paul Hitchin's departure for personal reasons is noted, the appointment of Claire Hinshelwood, with over 30 years of financial leadership experience including roles at BMI Group and Novartis, is a strong positive. Her expertise is expected to support the company's strategic goals of increased profitability and sustainable growth, providing continuity and new perspectives during a period of business transformation.
At the time of this filing, EVO was trading at $3.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.31 to $4.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.